Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.
The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) and found that B7-H3.CAR-Ts controlled the growth of pancreatic ductal adenocarcinoma, ovarian cancer and neuroblastoma in vitro and in orthotopic and metastatic xenograft mouse models, which included patient-derived xenograft. We also found that 4-1BB co-stimulation promotes lower PD-1 expression in B7-H3.CAR-Ts, and superior antitumor activity when targeting tumor cells that constitutively expressed PD-L1. We took advantage of the cross-reactivity of the B7-H3.CAR with murine B7-H3, and found that B7-H3.CAR-Ts significantly controlled tumor growth in a syngeneic tumor model without evident toxicity. These findings support the clinical development of B7-H3.CAR-Ts.
B7-H3 在多种肿瘤类型中高表达,而在正常组织中受限表达,使其成为免疫治疗的一个有吸引力的靶点。我们构建了针对 B7-H3 的嵌合抗原受体 (CAR) T 细胞 (B7-H3.CAR-Ts),并发现 B7-H3.CAR-Ts 在体外和原位及转移性异种移植小鼠模型(包括患者来源的异种移植模型)中控制了胰腺导管腺癌、卵巢癌和神经母细胞瘤的生长。我们还发现 4-1BB 共刺激可促进 B7-H3.CAR-Ts 中 PD-1 表达降低,并在针对持续表达 PD-L1 的肿瘤细胞时具有更好的抗肿瘤活性。我们利用 B7-H3.CAR 与鼠源 B7-H3 的交叉反应性,发现 B7-H3.CAR-Ts 在没有明显毒性的情况下,显著控制了同种异体肿瘤模型中的肿瘤生长。这些发现支持 B7-H3.CAR-Ts 的临床开发。